GLP-1 weight loss telehealth
Who prescribes semaglutide and tirzepatide online, and what you actually pay per month.
20 providers offer this. 5 include labs in the price. 5 accept insurance. Figures reflect what each provider publishes. * = provisional score.
Highest-scored providers
#1 
Ro 9.0 
Noom Med 8.9 
Mochi Health 7.5
Ro 9.0 Adults who want brand-name, FDA-approved GLP-1s with transparent cash pricing or help using commercial insurance, and who are comfortable with an online, message-based model.
Read the review → #2 Noom Med 8.9 Adults who want a flat-priced compounded GLP-1 plan with behavioural coaching and are outside AL, LA and MS.
Read the review → #3 Mochi Health 7.5 Insured adults who want video-based obesity care with a choice of brand or compounded GLP-1s and are comfortable paying membership and medication separately.
Read the review →Ranked guides
All providers
| Clinic | Score | Consult | Labs | Prescriber | Insurance | From |
|---|---|---|---|---|---|---|
| Ro A large direct-to-consumer telehealth company whose Ro Body programme prescribes branded GLP-1 medication, alongside its ED and hair-loss lines. | 9.0 | Async | Included | MD/DO + NP/PA | Yes | $39 first month membership |
| Noom Med Noom’s clinical programme adding GLP-1 prescribing to its behavioural weight-loss app. | 8.9 | Hybrid | Included | MD/DO + NP/PA | Cash | $129 first 4-week supply |
| Mochi Health A GLP-1 weight-loss telehealth provider with a low monthly membership fee and medication billed separately. | 7.5 | Video | Extra | MD/DO + NP/PA | Yes | $79/mo membership |
| Marek Health Also offers A telehealth clinic built around comprehensive bloodwork and physician-guided hormone optimisation, with TRT, peptide therapy and GLP-1 programmes. Known for an unusually deep lab panel. | 7.1 | Hybrid | Extra | MD/DO + NP/PA | Cash | $299 |
 Blokes Also offers A men’s telehealth clinic offering TRT, peptide therapy, GLP-1 weight loss and sexual health, with a sister brand for women. | 6.3 | Hybrid | Extra | MD/DO + NP/PA | Cash | $99/mo TRT on a 12-month plan |
 Calibrate A metabolic-health programme combining GLP-1 prescribing with a year-long coaching curriculum. | 5.6 | Video | Extra | NP/PA | Yes | $199/mo |
 OneTwenty Also offers Bloodwork-led longevity and hormone optimisation telehealth, with physician-guided TRT, GLP-1 weight management and peptide therapy built on comprehensive lab panels. | 9.2* | — | Included | — | Cash | $499/yr membership |
| Male Excel Also offers A men’s telehealth provider offering TRT, ED treatment and weight loss with at-home testing. | 8.2* | — | Included | — | Cash | $99/mo membership |
| Rex MD Also offers A men’s telehealth provider offering ED medication, TRT and weight-loss treatment. | 7.6* | Async | n/a | — | Cash | $2/dose |
 Found A weight-loss telehealth programme that pairs prescription medication, including GLP-1s where appropriate, with behavioural coaching. | 6.9* | Hybrid | Extra | — | Yes | $99/mo with insurance or $169/mo cash |
 Hone Health Also offers A large men’s hormone telehealth provider offering at-home lab testing, TRT and enclomiphene protocols, with a subscription model and physician video consults. | 6.9* | Video | Extra | MD/DO | Cash | $65 initial lab test |
 Maximus Also offers A men’s health telehealth brand offering TRT and enclomiphene protocols, a GLP-1 weight-loss programme, and hair and sexual health products. | 6.8* | Hybrid | Extra | MD/DO | — | $99.99/mo |
 Ways2Well Also offers A functional-medicine telehealth clinic offering bloodwork-driven hormone optimisation, TRT, peptide therapy and GLP-1 weight loss. | 6.8* | Video | Included | — | Cash | $125/mo Core care plan |
| Hims & Hers A publicly traded direct-to-consumer telehealth company offering weight-loss, sexual health, hair-loss and mental health treatment through an asynchronous model. | 6.7* | Async | Extra | MD/DO + NP/PA | Cash | $39 first month membership |
 Joi Also offers A women’s hormone telehealth clinic, sister brand to Blokes, offering HRT, peptide therapy and GLP-1 weight loss. | 6.2* | Hybrid | Extra | — | Cash | $149 hormone lab panel |
 Ivím Health A GLP-1 weight-loss telehealth provider with a membership model and compounded or branded medication options. | 5.3* | Hybrid | — | MD/DO + NP/PA | Cash | $65/mo compounded semaglutide |
 Gameday Men’s Health Also offers A franchise network of men’s health clinics offering TRT, weight loss and ED treatment, with in-clinic visits and some telehealth follow-up. | Not scored | — | — | MD/DO + NP/PA | Cash | $199/mo |
 Henry Meds A telehealth provider known for lower-cost GLP-1 weight-loss programmes, also offering TRT, through a flat monthly subscription. | Not scored | Hybrid | — | — | Cash | $179/mo all-in |
| PeterMD Also offers A physician-only TRT telehealth clinic with a pay-as-you-go model rather than a subscription, and a weight-loss programme. | Not scored | — | Extra | — | — | $79/mo on an annual plan |
 WeightWatchers Clinic WeightWatchers’ telehealth arm, formerly Sequence, prescribing GLP-1 medication alongside its behavioural programme. | Not scored | Hybrid | — | — | Yes | $25 first month |
Head-to-head comparisons
Tools for this decision
What these clinics prescribe
Reference records for the compounds offered in this category. Mechanism, dosing ranges, evidence level and regulatory status for each.
- Gonadorelin — Synthetic gonadotropin-releasing hormone, increasingly used alongside TRT to maintain testicular function.
- hCG — A placental glycoprotein hormone that mimics LH directly at the testis, the long-standing standard for preserving fertility on TRT.
- Liraglutide — The first-generation daily GLP-1 agonist, largely superseded by weekly agents but still widely prescribed.
- PT-141 — A melanocortin-4 selective agonist approved for hypoactive sexual desire disorder, acting centrally rather than vascularly.
- Semaglutide — A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss.
- Sermorelin — The first 29 amino acids of endogenous growth-hormone-releasing hormone, and the shortest fragment that retains full biological activity.
- Tesamorelin — A stabilised GHRH analog and the only growth-hormone secretagogue with a current FDA approval for a body-composition indication.
- Tirzepatide — A dual GIP and GLP-1 receptor agonist that produced greater weight loss than semaglutide in head-to-head trial data.
References
Regulatory and primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss ↗ · compounded and counterfeit semaglutide and tirzepatide
- FDA: Drug shortages database ↗ · shortage status that governs compounding
- HHS: Telehealth for patients ↗ · what to expect from a telehealth visit
- FDA: BeSafeRx, buying medicine online safely ↗ · how to check an online pharmacy
- NABP: Safe.Pharmacy verified websites ↗ · pharmacy accreditation lookup
- FSMB DocInfo: physician license lookup ↗ · check a prescriber is licensed
- FTC: Endorsements, influencers and reviews ↗ · disclosure rules for affiliate links
Published literature
- Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med 2025.PubMed 39536238 · doi:10.1056/NEJMoa2410819
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.J ASEAN Fed Endocr Soc 2022.PubMed 36578889 · doi:10.15605/jafes.037.02.14
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med 2025.PubMed 39555826 · doi:10.1056/NEJMoa2410027
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J Med 2024.PubMed 39476339 · doi:10.1056/NEJMoa2403664
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.Nat Med 2022.PubMed 36216945 · doi:10.1038/s41591-022-02026-4
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet 2021.PubMed 33667417 · doi:10.1016/S0140-6736(21)00213-0
Literature retrieved from PubMed on October 18, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.